On CNBC’s “Halftime Report Final Trades” on Tuesday, Jason Snipe, founder and chief funding officer of Odyssey Capital Advisors, stated he is staying long on AbbVie Inc. (NYSE:ABBV).
Supporting his view, Guggenheim analyst Vamil Divan maintained an AbbVie Buy score on Oct. 20, elevating the price target from $227 to $242.
Jim Lebenthal, companion at Cerity Partners, picked QUALCOMM Incorporated (NASDAQ:QCOM) as his last commerce.
According to current information, Satellite communications firm Iridium Communications (NASDAQ:IRDM) and Qualcomm Technologies have built-in Iridium knowledge providers into the Snapdragon Mission Tactical Radio, utilized by the U.S. authorities and authorised allied companions, on Oct. 14.
Don’t overlook to take a look at our premarket coverage here
Stephanie Link, chief funding strategist, head of funding options and portfolio supervisor at Hightower Advisors, named Aptiv PLC (NYSE:APTV).
Aptiv on Tuesday introduced the launch of its most superior radar expertise but, designed to fulfill rising demand for subsequent-era superior driver-help techniques (ADAS).
Joe Terranova, senior managing director at Virtus Investment Partners, picked Palo Alto Networks, Inc. (NASDAQ:PANW) as his last commerce.
Oppenheimer analyst Ittai Kidron, on Oct. 17, maintained Palo Alto Networks with an Outperform score and raised the value goal from $225 to $245.
Price Action:
- AbbVie shares fell 0.3% to shut at $231.39 on Tuesday.
- QUALCOMM shares rose 1.1% to shut at $168.83 in the course of the session.
- Aptiv shares gained 2.6% to shut at $85.59 on Tuesday.
- Palo Alto shares gained 1.2% to settle at $214.40.
Check This Out:
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.